Nation's largest lung cancer-focused nonprofit receives 2012 CEB Community Investment Grant to help stop lung cancer
March 22, 2012
is pleased to announce Corporate Executive Board (CEB), an
based leading research and advisory services firm, as one of its 2012 National Sponsors. As a National Sponsor, CEB helps LUNGevity in its quest to fund life saving research for treatments and cures for the nation's number one cancer killer, providing resources and helping build a community for those impacted by the disease.
As a recent recipient of the 2012 CEB Community Investment Grant, which serves to advance entrepreneurship, innovation and community building in cities and countries in need around the world, LUNGevity has entered into a relationship with CEB which includes both financial and in-kind support. In addition, LUNGevity is pleased to have the support of CEB volunteers.
"LUNGevity is honored to be a recipient of one of the 2012 CEB Community Investment Grants and welcome the company as a 2012 National Sponsor," said LUNGevity Foundation President
Andrea Stern Ferris
. "We've enjoyed a long standing, supportive relationship with CEB, and are excited to enter into this new phase. The support of companies like CEB is invaluable in our quest to start a national conversation about lung cancer and save lives."
"Our first connection to LUNGevity was through Breathe Deep DC in 2009. Since then, the Foundation has continued to grow dramatically, and we are pleased to play a part in that success. This year, as a National Sponsor, we are looking forward to having our staff become involved in more LUNGevity events around the country," said
, CEB Chairman and CEO. "We are proud to join Pfizer as a LUNGevity national partner and encourage other companies to support the organization's efforts to cure lung cancer."
About LUNGevity Foundation
The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.